Actimab-A, a CD33-targeted Actinium-225 radioconjugate, drives potent mutation-agnostic efficacy in AML models

Blood Neoplasia · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles